PP2A‐B55 and its adapter proteins IER2 and IER5 regulate the activity of RB family proteins and the expression of cell cycle‐related genes

Abstract

The retinoblastoma (RB) tumour suppressor protein regulates cell proliferation, motility, differentiation and apoptosis. The phosphorylation state of RB is modulated by kinases and phosphatases, and RB exhibits phosphorylation‐sensitive interactions with E2F family transcription factors. Here, we characterize RB dephosphorylation by protein phosphatase 2A (PP2A). The growth factor‐inducible immediate early response (IER) proteins IER2 and IER5 possess an adapter‐like function in which IER proteins bind to both PP2A and its target proteins and enhance PP2A activity towards the proteins. IER2 interacts with RB and facilitates dephosphorylation of RB at T821/T826 by PP2A. In IER2 knockdown cells, elevated phosphorylation of RB resulted in reduced binding of RB to the promoters and derepression of cyclin D1 and p21. IER5 binds to both RB and RB‐like 1 (p107/RBL1), enhances dephosphorylation of these proteins by PP2A and represses the expression of various cell cycle‐related genes. However, IER2‐regulated dephosphorylation at T821/T826 is not necessary for the repression function of RB in cell mobility‐related gene expression. Our data identify PP2A adapter proteins as critical regulators of RB family proteins and suggest that the phosphorylation status of RB differentially affects gene expression.

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition

“…New treatment options and combinations are therefore needed. Single-dose radiosurgery of melanoma brain metastases achieves 1-year local control rates of 86% [ 86 , 87 ] and comparable outcomes are achieved in larger metastases with hypofractionated radiosurgery delivered in three to five fractions [ 88 ]. Retrospective analyses suggest that the combination of stereotactic radiotherapy and immune checkpoint inhibitors achieves a survival benefit without increased toxicity compared to stereotactic radiotherapy or immune checkpoint inhibitors alone [ 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 ].…”

p53-Dependent Cytoprotective Mechanisms behind Resistance to Chemo-Radiotherapeutic Agents Used in Cancer Treatment

“…PARP1 stabilises IER5 protein and along with Ku70-IER5 promotes NHEJ [ 83 ]. IER5 also induces G2/M cell cycle arrest by inhibiting CDC25B transcription vis dephosphorylation by PP2A-B55 phosphatase [ 84 , 85 , 86 ]. Thus, IER5 appears to exert its function in a context-dependent manner involving its binding to various partners, but these diverse functions of IER5 may all contribute to stress resistance in both normal and cancer cells.…”